Portopulmonary hypertension.

Authors:
Sarfraz Saleemi

Ann Thorac Med 2010 Jan;5(1):5-9

King Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.

Portopulmoanry hypertension (POPH) is a form of pulmonary arterial hypertension (PAH) associated with portal hypertension with or without underlying chronic liver disease. POPH is increasingly recognized and recent evidence suggests that it is one of the leading causes of PAH. The pathophysiology of POPH is poorly understood although the pathological changes in pulmonary vasculature in advanced POPH are similar to those seen in idiopathic pulmonary hypertension. The prognosis in patients with liver disease who also suffer from significant POPH is considered to be poor. Higher degree of pulmonary artery pressure (PAP) may preclude a patient from liver transplant as mortality in these patients is high. The treatment with vasodilator therapy has shown to improve both hemodynamics and clinical outcome in POPH in retrospective studies and in some case series. The aim of medical management is to bring PAP <35 mmHg that may make a patient with POPH and advanced liver disease eligible for liver transplant, which otherwise would have been denied because of high PAP.

Download full-text PDF

Source
http://dx.doi.org/10.4103/1817-1737.58953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841810PMC
January 2010
3 Reads

Publication Analysis

Top Keywords

liver disease
8
poph
6
changes pulmonary
4
pathological changes
4
patients high
4
pulmonary vasculature
4
advanced poph
4
vasculature advanced
4
transplant mortality
4
mortality patients
4
high treatment
4
vasodilator therapy
4
leading pah
4
suggests leading
4
pah pathophysiology
4
pathophysiology poph
4
liver transplant
4
poph understood
4
treatment vasodilator
4
understood pathological
4

Similar Publications